US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.67

+0.05630.45%

Volume:26.82K

Turnover:339.03K

Market Cap:699.87M

PE:-7.82

High:12.67

Open:12.61

Low:12.60

Close:12.61

Loading ...

Overview Company News Filings

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

Press Release: Brookfield Real Assets Income Fund Inc. Declares Q2 2025 Distribution Schedule

Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%

MT Newswires Live

Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

CPF Special, MediSave and Retirement Accounts’ interest rate remains at 4% for Q2 2025

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

RA International Announces Secondary Trading Facility Post-AIM Cancellation

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Silver Housing Bonus scheme extended to more private property owners who downsize

RA International to Delist from AIM Following Shareholder Approval

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

Press Release: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

Brookfield Real Assets Income Fund Inc. Announces Portfolio Management Team Changes

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.6663,"timestamp":1744898550187,"preClose":12.61,"halted":0,"volume":26816,"delay":0,"floatShares":55254696,"shares":55254696,"eps":-1.61933,"marketStatus":"Trading","change":0.0563,"latestTime":"04-17 10:03:32 EDT","open":12.6099,"high":12.6695,"low":12.595,"amount":339025.061056,"amplitude":0.005908,"askPrice":12.67,"askSize":50,"bidPrice":12.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.61933,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1744920000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.61,"preHourTrading":{"tag":"盘前","latestPrice":12.6595,"preClose":12.61,"latestTime":"08:58 EDT","volume":200,"amount":2531.9,"timestamp":1744894689662},"postHourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.61,"latestTime":"16:05 EDT","volume":93,"amount":1169.17,"timestamp":1744833909068},"volumeRatio":1.583825},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55254696,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.583825,"shares":55254696,"dividePrice":1.416,"high":12.6695,"amplitude":0.005908,"preClose":12.61,"low":12.595,"week52Low":11.87,"pbRate":"--","week52High":13.77,"institutionHeld":0,"latestPrice":12.6663,"committee":0.333333,"eps":-1.61933,"divideRate":0.111793,"volume":26816,"delay":0,"ttmEps":-1.61933,"open":12.6099,"prevYearClose":13.32,"prevWeekClose":12.53,"prevMonthClose":13.16,"prevQuarterClose":13.16,"fiveDayClose":12.42,"twentyDayClose":13.13,"sixtyDayClose":13.44},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMS","IIM","ARTV","SLE","R","BK4232","RA","BK4139","BK4077","BK4022"],"gpt_icon":0},{"id":"2525834416","title":"AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2525834416","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525834416?lang=en_us&edition=fundamental","pubTime":"2025-04-08 14:00","pubTimestamp":1744092000,"startTime":"0","endTime":"0","summary":"RINVOQ is the first and only oral Janus kinase  inhibitor approved in the European Union  to treat adult patients with giant cell arteritis . The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission 1. This marks the eighth approved indication for RINVOQ in the EU2. NORTH CHICAGO, Ill., April 8, 2025 /PRNewswire/ -- AbbVie  today announced that the European Commission  granted marketing authorization to RINVOQ  for the treatment of giant cell arteritis  in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.GCAis an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","IE00B42XCP33.USD","LU1878469433.USD","CPK","LU2237443465.HKD","LU0965509101.SGD","LU1093756325.SGD","RA","SG9999015978.USD","BK4559","LU2023251221.USD","IE00BDGV0183.EUR","SG9999015986.USD","TAK","LU2129689431.USD","SG9999015945.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4007","LU1718418525.SGD","LU1551013425.SGD","LU1162221912.USD","LU1037948897.HKD","IE0004445239.USD","LU1551013342.USD","IE00B2B36J28.USD","BK4156","LU0198837287.USD","IE00BVYPNV92.GBP","LU2087621335.USD","LU2237443895.HKD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU1003077747.HKD","LU0320765646.SGD","ALT","EC","LU0211327993.USD","LU2237443622.USD","BK4139","IE0009355771.USD","LU1934455194.USD","LU2237443978.SGD","LU0861579265.USD","LU0965508806.USD","ABBV","LU0211328371.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2523633325","title":"Press Release: Brookfield Real Assets Income Fund Inc. Declares Q2 2025 Distribution Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2523633325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523633325?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:34","pubTimestamp":1743194040,"startTime":"0","endTime":"0","summary":"NEW YORK, March 28, 2025  -- Brookfield Real Assets Income Fund Inc.   today announced that its Board of Directors  declared the Fund's monthly distributions for April, May and June 2025.April 2025   April 10, 2025   April 10, 2025   April 24, 2025          $0.1180. May 2025     May 8, 2025      May 8, 2025      May 22, 2025            $0.1180. June 2025    June 12, 2025    June 12, 2025    June 26, 2025           $0.1180. Investing involves risk; principal loss is possible. Past performance is not a guarantee of future results.Brookfield Real Assets Income Fund Inc. is distributed by Foreside Fund Services, LLC.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2522829878","title":"Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522829878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522829878?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025. Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1. Oral formulation optimization study on track to support initiation of clinical trials for MET-224 and MET097 , with MET-224 data expected in late 2025. Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027. NEW YORK, March 26, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial results and provided an update on pipeline progress.With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be anot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4139","MTSR","IPO","RA","BK4097","PRGS"],"gpt_icon":0},{"id":"2522181554","title":"Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522181554","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522181554?lang=en_us&edition=fundamental","pubTime":"2025-03-26 15:21","pubTimestamp":1742973671,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  said that China's National Medical Products Administration  approved an application for a Phase 2 clinical trial of HLX79 injection in combination with Hanlikang for the treatment of active glomerulonephritis, according to a filing made on Tuesday with the Hong Kong bourse.HLX79 is a sialidase fusion protein made by combining a human sialidase enzyme with a human monoclonal antibody.Hanlikang is approved in Mainland China for non-Hodgkin's lymphoma , chronic lymphocytic leukemia , and rheumatoid arthritis .The pharmaceutical company's shares were up 3% in recent trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02696","RA"],"gpt_icon":0},{"id":"2522707632","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707632?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Initial data for AlloNK from autoimmune program expected H1 2025. Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025. Strengthened key leadership with cell therapy and autoimmune expertise across organization. Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026. SAN DIEGO, March 24, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139","BK4232","R","BK4077","RA","BK4022","SLE"],"gpt_icon":0},{"id":"2518878440","title":"CPF Special, MediSave and Retirement Accounts’ interest rate remains at 4% for Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518878440","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518878440?lang=en_us&edition=fundamental","pubTime":"2025-03-12 03:07","pubTimestamp":1741720057,"startTime":"0","endTime":"0","summary":"Rates for the Ordinary Account and HDB housing loans are also unchanged","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/companies-markets/cpf-special-medisave-and-retirement-accounts-interest-rate-remains-4-q2-2025","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/companies-markets/cpf-special-medisave-and-retirement-accounts-interest-rate-remains-4-q2-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["LU0868486357.SGD","LU0348744763.USD","LU0541501648.USD","LU0456842615.SGD","LU1804176565.USD","LU2226246903.HKD","RA","BK4017","HDB","LU0197773673.USD","LU0918141705.HKD","LU1805238398.USD","BK4207","LU0630378429.USD","LU0348814723.USD","LU2008162690.USD","BK4588","LU0348816934.USD","LU0431992006.USD","LU0630378692.HKD","LU0390134368.USD","LU0918141887.USD","BK4585","LU0197773160.USD","BK4566","SG9999014021.USD","LU0541502299.USD","LU1791710400.SGD","LU2177674079.SGD","SG9999014013.SGD","LU0797268264.HKD","SG9999014005.SGD","LU1854104046.USD","BK4535","BK4211","LU0536402901.SGD","LU1267930656.SGD","LU1791710582.SGD","CPF","LU2279701549.SGD","LU0708995666.HKD","LU0197229882.USD","LU0287143357.SGD","LU0528227936.USD","LU1282648689.USD","LU0231203729.USD","LU2265009873.SGD","LU1105468828.SGD","BK4523"],"gpt_icon":0},{"id":"2518482877","title":"Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518482877","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518482877?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD. CARLSBAD, Calif., March 11, 2025  -- Exagen Inc. ,a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.Achieved key commercial milestone with completion of 1,000,000th patient tested by AVISE CTD. Featured five abstracts at the 2024 American College of Rheumatology  annual meeting highlighting Exagen’s innovative research on novel T Cell biomarkers for Lupus and sero-negative autoantibodies for rheumatoid arthritis, in addition to a plenary presentation in collaboration with Johns Hopkins University, highlighting a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis patients. Secured New York State Department of Health ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exagen-inc-reports-strong-fourth-120000907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","XGN","ACR","BK4110","RA","SLE","BK4139"],"gpt_icon":0},{"id":"2518206289","title":"RA International Announces Secondary Trading Facility Post-AIM Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518206289?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:17","pubTimestamp":1741630640,"startTime":"0","endTime":"0","summary":"An update from RA International Group Plc ( ($GB:RAI) ) is now available. RA International Group PLC has announced the details of a secondary marke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ra-international-announces-secondary-trading-facility-post-aim-cancellation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ra-international-announces-secondary-trading-facility-post-aim-cancellation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4557","RA","POST","AIM","BK4139","BK4212"],"gpt_icon":0},{"id":"2518423051","title":"Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518423051","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518423051?lang=en_us&edition=fundamental","pubTime":"2025-03-09 02:00","pubTimestamp":1741456800,"startTime":"0","endTime":"0","summary":"Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg. Patients treated withbaricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo. Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-baricitinib-delivered-high-rates-180000752.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-baricitinib-delivered-high-rates-180000752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1267930730.SGD","LU0354030511.USD","LU0823416689.USD","LU0198837287.USD","LU2461242641.AUD","LU1023059063.AUD","IE0002141913.USD","BNTX","SG9999014914.USD","SG9999014880.SGD","LU2237443895.HKD","LU1093756325.SGD","LU2468319806.SGD","LU0672654240.SGD","LU2361045086.USD","IE00BK4W5M84.HKD","LU2491049909.HKD","LU0471298694.HKD","LU2237443978.SGD","LU1069344957.HKD","IE00B4R5TH58.HKD","LU2602419157.SGD","LU1548497426.USD","LU2106854487.HKD","LU0203201768.USD","BK4157","LU1720051017.SGD","LU2361044949.HKD","BK4532","RA","BK4533","SGXZ81514606.USD","LU0097036916.USD","LU2023250504.SGD","SG9999015945.SGD","LU0471298777.SGD","LU1878469433.USD","LU1061106388.HKD","LU2237443622.USD","LU0320765059.SGD","ALC","MACE","SG9999017495.SGD","LLY","ALT","INCY","LU1868836914.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","BK4548"],"gpt_icon":1},{"id":"2517959757","title":"Silver Housing Bonus scheme extended to more private property owners who downsize","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959757","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517959757?lang=en_us&edition=fundamental","pubTime":"2025-03-05 03:58","pubTimestamp":1741118303,"startTime":"0","endTime":"0","summary":"Scheme incentivises seniors to sell their homes to move into a smaller HDB flat and boost their retirement income ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/property/silver-housing-bonus-scheme-extended-more-private-property-owners-who-downsize","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/property/silver-housing-bonus-scheme-extended-more-private-property-owners-who-downsize","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["RA","5OC.SI","BK6045","BK6520"],"gpt_icon":0},{"id":"2516037127","title":"RA International to Delist from AIM Following Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2516037127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516037127?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:47","pubTimestamp":1740761269,"startTime":"0","endTime":"0","summary":"RA International Group Plc ( ($GB:RAI) ) just unveiled an update. RA International Group PLC announced the approval of a resolution to cancel the a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ra-international-to-delist-from-aim-following-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ra-international-to-delist-from-aim-following-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIM","RA","BK4139","BK4557"],"gpt_icon":0},{"id":"2514313647","title":"AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313647","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313647?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:00","pubTimestamp":1740726000,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the pivotal Phase 3SELECT-GCA trial that evaluated the efficacy and safety ofupadacitinib in adults with giant cell arteritis 1. The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission, were met1. GCAis an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2. NORTH CHICAGO, Ill., Feb. 28, 2025 /PRNewswire/ -- AbbVie  today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  adopted a positive opinion recommending the approval of upadacitinib for the treatment of adult patients with GCA. The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA.*Sustained remission is defined as having ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1061106388.HKD","LU0256863902.USD","SG9999001440.SGD","LU0708994859.HKD","SG9999003800.SGD","LU0949170772.SGD","BK4581","LU0661504455.SGD","CPK","TAK","LU0545039389.USD","LU2237443382.USD","LU2468319806.SGD","BK4139","LU1989771016.USD","LU0122379950.USD","LU0861579265.USD","LU0795875086.SGD","LU1267930573.SGD","LU0882574055.USD","LU0114720955.EUR","LU0820561818.USD","LU2237443895.HKD","LU0689472784.USD","LU1244550221.USD","LU1718418525.SGD","LU2237443978.SGD","LU1003077747.HKD","CHMP","LU2347655156.SGD","LU1551013342.USD","BK4197","ALT","BK4566","IE00BJJMRZ35.SGD","LU0553294199.USD","LU1585245621.USD","BK4534","BK4007","BK4599","ABBV","LU1934455863.HKD","LU1878469433.USD","RA","LU0198837287.USD","LU0943347566.SGD","BK4588","LU1037948541.HKD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2514135859","title":"Press Release: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514135859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514135859?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:15","pubTimestamp":1740690900,"startTime":"0","endTime":"0","summary":"-- Announced rosnilimab, a PD-1 depleter and agonist, achieved positive. results from Phase 2b rheumatoid arthritis  trial and highest-ever. -- Full clinical and translational data for rosnilimab in RA in Q2 2025. -- Top-line Phase 2 data for rosnilimab in ulcerative colitis , moved up. -- Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122. antagonist, and Phase 1a trial to initiate this quarter for ANB101, our. -- Announced exclusive global license agreement with Vanda Pharmaceuticals. to develop and commercialize imsidolimab, an IL-36R antagonist. -- Year-end 2024 cash and investments of $420 million and reiterating cash. SAN DIEGO, Feb. 27, 2025  -- AnaptysBio, Inc. , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.once-monthly doses, achieved positive results in 424-patient Phase 2b RA. trial and hi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053666078.USD","ANAB","BK4107","ACR","TEP","BK4110","BK4588","L","RA","BK4585"],"gpt_icon":0},{"id":"2514804598","title":"Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804598","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804598?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:45","pubTimestamp":1740660300,"startTime":"0","endTime":"0","summary":"Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year. Delivered full-year 2024 adjusted EBITDA of $8.6 million. Generated ZYNRELEF Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle  in December 2024. U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI patents which expire in 2035. CARY, N.C., Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc.  , a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2024, and highlighted recent corporate updates.Partnership with Crosslink Network, LLC expands the promotional effort for ZYNRELEF within the orthopedic surgery marketplace for post-operative pain.Cash, cash equivalents, and short-term investments were $59.3 million as of December 31, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/heron-therapeutics-announces-fourth-quarter-124500761.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heron-therapeutics-announces-fourth-quarter-124500761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MEC","BK4563","AC","CINV","RA","BK4161","BK4135","HRTX","BK4139"],"gpt_icon":0},{"id":"2514180530","title":"Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514180530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514180530?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus  expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S.Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions. Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028. CAMBRIDGE, Mass., Feb. 27, 2025  -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2024.CLN-978 : Systemic lupus erythematosus and rheumatoid arthritis. The global Phase 1 study in moderate to severe SLE is ongoing with site expansion in the United States, Europe and Australia, and the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-provides-corporate-reports-120000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","CGEM","RA","SLE","BK4139"],"gpt_icon":0},{"id":"2511366259","title":"Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2511366259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511366259?lang=en_us&edition=fundamental","pubTime":"2025-02-14 20:30","pubTimestamp":1739536200,"startTime":"0","endTime":"0","summary":"-- Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea. -- New OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms,\"Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chronic and life-threatening disease. We are enthusiastic about the potential for IHL-42X, an oral, once-daily treatment that uniquely targets physiological pathways responsible for the airway obstruction characteristic of OSA. We achieved a key milestone for our OSA program, reporting positive top-line results from a pharmacokinetics  and safety study of IHL-42X, conducted alongside our global Phase 2/3 RePOSA study,\" said Joel Latham, Incannex's President and Chief Executive Officer. and safety study of IHL-42X, a novel, oral fixed-dose combination of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4167","BK4563","BK4181","BK4085","IH","PK","HCSG","BK4007","BK4510","AHI","BK4218","IXHL","RA","BK4097"],"gpt_icon":0},{"id":"2511413525","title":"AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511413525","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511413525?lang=en_us&edition=fundamental","pubTime":"2025-02-13 18:11","pubTimestamp":1739441460,"startTime":"0","endTime":"0","summary":"AnaptysBio, Inc.  shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17% loss over the past four weeks.The stock price soared after AnaptysBio announced meeting the primary endpoint in a mid-stage study of its investigational candidate, rosnilimab, for moderate-to-severe rheumatoid arthritis  across all three doses compared to placebo, at week 12. Rosnilimab is a depleter and agonist of PD-1+ T cells. Per the data readout, the candidate achieved statistical significance with at least one dose and numerical superiority at all doses. The phase IIb RENOIR study also achieved certain key secondary endpoints at Week 12, with the highest recorded responses at Week 14 despite higher-than-usual placebo rates. Rosnilimab was generally safe and overall well-tolerated in the study. ANAB expects to share full 28-week data from the RA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anaptysbio-anab-surges-30-5-101100919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","RA","BK4139","BK4007","ANAB"],"gpt_icon":0},{"id":"2511153598","title":"Brookfield Real Assets Income Fund Inc. Announces Portfolio Management Team Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2511153598","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511153598?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:42","pubTimestamp":1739396520,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 12, 2025  -- Brookfield Public Securities Group LLC  today announced upcoming changes to the Brookfield Real Assets Income Fund Inc.  portfolio management team.Riley O’Neal, CFA, Director of Risk Management, will join the portfolio management team for RA. Riley has been a member of PSG’s risk management team since joining the firm in 2016 and currently serves as director of risk management. To address current market dynamics, PSG believes it is critical that it continue to invest in the quantitative resources of the firm and align those resources with its investment teams. PSG believes Riley will bring a valuable quantitative analysis skillset to his role as co-portfolio manager for the Fund.Paula Horn, PSG’s President and Chief Investment Officer, also will join the Fund’s portfolio management team. Paula brings 31 years of investment experience, a wealth of credit knowledge, valuable macro insights and facilitates connectivity across Brookfield. Both portfolio manageme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brookfield-real-assets-income-fund-214200893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4204","BK4531","BK4552","BK4506","BK4120","BK4510","RA","BK4503","GOTU","TISI"],"gpt_icon":0},{"id":"2510930652","title":"Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data","url":"https://stock-news.laohu8.com/highlight/detail?id=2510930652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510930652?lang=en_us&edition=fundamental","pubTime":"2025-02-12 23:00","pubTimestamp":1739372432,"startTime":"0","endTime":"0","summary":"Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-says-anaptysbio-handing-of-placebo-raise-doubt-about-phase-2-ra-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-says-anaptysbio-handing-of-placebo-raise-doubt-about-phase-2-ra-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RA","ANAB"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2025-06-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-12","defaultRemindTime":1749735000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-26","payableDate":"2025-06-12","currency":"USD","dateTimestamp":1749700800000,"payDate":"2025-06-26"},{"date":"2025-05-08","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-08","defaultRemindTime":1746711000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-22","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746676800000,"payDate":"2025-05-22"},{"date":"2025-04-10","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-24","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-24"},{"date":"2025-03-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-27","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-03-27"},{"date":"2025-02-06","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-06","defaultRemindTime":1738852200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-20","payableDate":"2025-02-06","currency":"USD","dateTimestamp":1738818000000,"payDate":"2025-02-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{}}}